AxoGen Raises 2026 Revenue Floor to $290 Million, Up 29%
Key Facts
On October 28, AxoGen raised its 2026 revenue outlook to at least $290 million, equivalent to year-over-year growth of at least 29%, according to a company filing with the U.S. Securities and Exchange Commission. The guidance comes as the company reported quarterly revenue of $75.8 million in the third quarter, up 26.2% from $60.1 million in the same period of 2025. Chief Executive Michael Dale said, "Strong growth across all markets continues to validate our market development strategies and the strength of our commercial execution." The company said its growth extended across multiple segments, alongside improved insurance coverage and commercial reimbursement. It also announced positive coverage decisions from Elevance and Aetna for Avance, bringing its commercial coverage to about 96% of covered lives in the U.S.
The new outlook is higher than the company’s previous 2026 forecast, which pointed to growth of at least 18% and revenue of $265.7 million. AxoGen reported revenue of $225.2 million in 2025, up 20.2% from $187.3 million in 2024. The new floor is based on a combination of growth in the existing business and a contribution from the acquisition completed during the year. The company said organic revenue, excluding BioCircuit, would be at least $283 million, representing growth of at least 26%. It added that it expects a gross margin of at least 73% and positive free cash flow for the full year.
For third-quarter performance, gross profit margin was 74.8%, compared with 76.6% in the third quarter of 2025. Net income rose to $2.3 million, or $0.04 per share, from $0.7 million, or $0.01 per share, a year earlier. The company said year-to-date revenue growth spanned the extremities, oral and maxillofacial surgery, head and neck, and breast segments. It attributed the performance to an increase of more than 20% in account productivity year over year, as well as expanded sales force coverage and improved commercial coverage and reimbursement. Dale said the company believes it is well positioned to achieve its 2026 revenue guidance and long-term targets.
AxoGen completed its acquisition of BioCircuit Technologies, developer of NerveTape, on October 1, adding a specific component to its annual outlook. The company expects BioCircuit to contribute at least $7 million of 2026 revenue, within the targeted total of at least $290 million. That puts the minimum expected organic revenue at $283 million, excluding the deal’s impact. These figures distinguish expected growth from AxoGen’s existing business from the contribution attributed to the acquired company. The distinction comes alongside the company’s expectation of maintaining a gross margin of at least 73% and generating positive free cash flow during the year.
AxoGen is also working to expand Avance’s use into nerve reconstruction procedures associated with the prostate, following clinical results it described as positive. The company said it decided to begin market development for this use in 2027. In an update presented on November 9, it said more than 220 patients had undergone nerve reconstruction using Avance, and 117 patients had completed at least six months of follow-up. These figures provide clinical context for the announced market development step, while the 2026 financial outlook remains tied to revenue for the current year and BioCircuit’s contribution. The company estimated the potential market for prostate-related nerve reconstruction procedures at about $754 million, based on about 110,000 cases annually and a weighted average selling price of about $7,000 per procedure.
In trading, AXGN closed at $55.93 on November 13, 2026, according to EL7 data. The closing price followed the October 28 announcement of the outlook and third-quarter results, then the company’s November 9 update on its prostate program. This sequence places the quarterly results, annual outlook and clinical program developments in a single timeline, with the closing price serving as a reference for the November 13 session. The company’s next announced step in this effort is to begin market development for Avance’s use in prostate procedures during 2027.